Interesting Stocks

[BlueWolf]

Looks like IONQ is acquiring SKYT. Should be good for both companies.

[BlueWolf]

Here’s an another interesting company, Fauna Robotics, making humanoid robots. They just got gobbled up by Amazon.

[BlueWolf]

Came across another fascinating stock this week, COMPASS Pathways (CMPS). This one is a super speculator. They’re pre revenue, but they’re developing psilocybin therapy for treatment-resistant depression. Shades of Timothy Leary. I’m gonna have to keep an eye on this one just to see what happens here. I’m not saying this is an investment opportunity yet, but it’ll be fun to follow.

[jiesen]

The chart for CMPS is impressive, in that it went from under $4 to over $10 in a year. But the numbers on their books don't make any sense to me... They spend $100M+ every year (half on Sales/admin), but have 0 revenues. Maybe they're just getting started, but with no sales numbers to look at, I don't know if $10/shr is good or bad. Are they selling the therapy, or just selling stock?

[jiesen]

...it'll be fun to follow.

yep, it's a curious one, and I'm interested to see how it plays out, too.

[BlueWolf]

The chart for CMPS is impressive, in that it went from under $4 to over $10 in a year. But the numbers on their books don't make any sense to me... They spend $100M+ every year (half on Sales/admin), but have 0 revenues. Maybe they're just getting started, but with no sales numbers to look at, I don't know if $10/shr is good or bad. Are they selling the therapy, or just selling stock?

They’re pre-revenue. They are working on getting FDA approval for their treatment.

[jiesen]

Yeah, that's what I figured. Question is, can they make back a half-billion in R&D costs by selling therapy treatments? Without seeing what the market is willing to pay for this stuff, it's hard to justify a $4 share price, let alone $14. Maybe it works out, or approval gives this stock a quick bump up and a chance to get out with a few bucks in profit, but I think it's looking like a long shot to become a viable ongoing business (as most pre-approval drug companies are).